TILMONT, Rémi, YAKOUB-AGHA, Ibrahim, EIKEMA, Diderik-Jan, ZINGER, Nienke, HANEL, Michael, SCHAAP, Nicolaas, HERRERA ARROYO, Concepcion, SCHUERMANS, Christine, BETHGE, Wolfgang Andreas, ENGELHARDT, Monika, KUBALL, Jürgen, MICHIELI, Mariagrazia, SCHUB, Natalie, WILSON, Keith M. O., BOURHIS, Jean-Henri, MATEOS, Maria-Victoria, ROBIN, Nimmy, REXHAUSEN, Jost E., KRÖGER, Nicolaus, MORALEDA, Jose Maria, SICA, Simona, HAYDEN, Patrick, BEKSAC, Meral, SCHÖNLAND, Stefan und MANIER, Salomon, 2024. P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT. Freiburg: Universität.
Elsevier - Harvard (with titles)Tilmont, R., Yakoub-Agha, I., Eikema, D.-J., Zinger, N., Hanel, M., Schaap, N., Herrera Arroyo, C., Schuermans, C., Bethge, W.A., Engelhardt, M., Kuball, J., Michieli, M., Schub, N., Wilson, K.M.O., Bourhis, J.-H., Mateos, M.-V., Robin, N., Rexhausen, J.E., Kröger, N., Moraleda, J.M., Sica, S., Hayden, P., Beksac, M., Schönland, S., Manier, S., 2024. P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT. Universität, Freiburg. https://doi.org/10.1097/01.hs9.0000846696.43332.f6
American Psychological Association 7th editionTilmont, R., Yakoub-Agha, I., Eikema, D.-J., Zinger, N., Hanel, M., Schaap, N., Herrera Arroyo, C., Schuermans, C., Bethge, W. A., Engelhardt, M., Kuball, J., Michieli, M., Schub, N., Wilson, K. M. O., Bourhis, J.-H., Mateos, M.-V., Robin, N., Rexhausen, J. E., Kröger, N., Moraleda, J. M., Sica, S., Hayden, P., Beksac, M., Schönland, S., & Manier, S. (ca. 2024). P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT [Cd]. Universität. https://doi.org/10.1097/01.hs9.0000846696.43332.f6
Springer - Basic (author-date)Tilmont R, Yakoub-Agha I, Eikema D-J, Zinger N, Hanel M, Schaap N, Herrera Arroyo C, Schuermans C, Bethge WA, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson KMO, Bourhis J-H, Mateos M-V, Robin N, Rexhausen JE, Kröger N, Moraleda JM, Sica S, Hayden P, Beksac M, Schönland S, Manier S (2024) P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Tilmont, Rémi/ Yakoub-Agha, Ibrahim/ Eikema, Diderik-Jan/ Zinger, Nienke/ Hanel, Michael/ Schaap, Nicolaas/ Herrera Arroyo, Concepcion/ Schuermans, Christine/ Bethge, Wolfgang Andreas/ Engelhardt, Monika/ Kuball, Jürgen/ Michieli, Mariagrazia/ Schub, Natalie/ Wilson, Keith M. O./ Bourhis, Jean-Henri/ Mateos, Maria-Victoria/ Robin, Nimmy/ Rexhausen, Jost E./ Kröger, Nicolaus/ Moraleda, Jose Maria/ Sica, Simona/ Hayden, Patrick/ Beksac, Meral/ Schönland, Stefan/ Manier, Salomon, P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT, Freiburg 2024.